J&J beats analyst earnings estimates, offers upbeat guidance
The company doesn’t think the threat of tariffs will shrink its profits in 2025.
Johnson & Johnson rose in early trading after it reported earnings that beat analysts’ estimates and gave upbeat guidance.
The company reported adjusted earnings per share of $2.77, compared to the $2.58 analysts polled by Factset were expecting. It also reported $21.9 billion in sales, compared to the $21.5 billion analysts were penciling in. J&J’s sales growth was driven by oncology and cardiovascular drugs, which made up for a drag in Stelara, its blockbuster immunology drug whose patent expired in 2023.
J&J said it expects full-year EPS to grow by 6.2%, even with pricing in tariffs costs. President Trump has kept the pharmaceutical industry on its toes, consistently threatening to put tariffs on the industry to pressure companies to reshore manufacturing. According to J&J, the company has more manufacturing in the US than in any other country, and it recently announced a multibillion-dollar investment in US manufacturing.